前列腺癌自适应治疗结局的数学生物标志物
该回顾性建模与验证研究利用2项临床试验中53例前列腺癌患者(40例去势敏感、13例转移性去势抵抗)的首周期PSA动力学,构建基于双种群微分方程的数学生物标志物。
要点
- 首周期PSA动力学衍生的自适应治疗评分可预测前列腺癌自适应治疗下的TTP。
- 转移性去势抵抗队列中评分及预期TTP与OS显著相关,优于传统PSA指标。
核心结论
- 基于首周期PSA动力学的机制性数学生物标志物可准确预测患者个体化结局与生存,优于传统现象学PSA监测。
- 这些易获取的指标可作为数学决策支持框架,用于将患者分层至个体化治疗方案。
研究设计与样本
- 回顾性建模与验证研究,使用2项独立非随机临床试验的纵向数据。
- 去势敏感前列腺癌队列40例(1996年6月至2006年9月),转移性去势抵抗前列腺癌队列13例(2015年4月至2022年1月),共53例。
- 采用双种群微分方程模型描述药物敏感与耐药细胞的竞争动力学,统计分析时间为2025年1月至2026年5月。
主要发现
- 转移性去势抵抗队列长期生存数据显示,自适应治疗评分与预期TTP均与延长OS显著相关,而标准经验性PSA指标与OS无关联。
关键数值与推荐
- 自适应治疗评分由首周期PSA动力学衍生,同时衍生预期TTP与预期平均每日剂量。
- 性能对照标准现象学PSA指标(如PSA最低值、达最低值时间、倍增时间)进行基准测试。
临床怎么用
- 可利用首周期PSA动力学计算的自适应治疗评分辅助制定个体化治疗间歇安排。
- 该评分与预期TTP可用于患者分层,识别可能从自适应治疗中获益更久的人群。
局限性
- 回顾性建模与验证研究,样本量较小(去势敏感40例、去势抵抗13例),非随机设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adaptive therapy is an evolution-based treatment paradigm that has been shown to delay resistance in prostate cancer through treatment breaks that control, rather than minimize, tumor burden. However, patient responses are highly heterogeneous, and there is a significant unmet clinical need for biomarkers to personalize treatment scheduling. OBJECTIVE: To develop and retrospectively validate mathematical biomarkers that predict time to progression (TTP), mean daily dose, and overall survival (OS) under adaptive therapy from first-cycle prostate-specific antigen (PSA) dynamics. DESIGN, SETTING, AND PARTICIPANTS: This retrospective modeling and validation study used longitudinal, nonrandomized clinical trial data from 2 independent cohorts: 40 patients with castrate-sensitive prostate cancer (CSPC) (June 1996 to September 2006) and 13 patients with metastatic castrate-resistant prostate cancer (mCRPC) (April 2015 to January 2022). A 2-population differential equation model was used to describe the overall tumor growth through the competing dynamics of drug-sensitive and drug-resistant cells. The statistical analysis was conducted from January 2025 to May 2026. EXPOSURES: Patients received either intermittent androgen deprivation therapy (for CSPC) or adaptive abiraterone acetate (for mCRPC). The initial treatment cycle served as the exposure period to extract longitudinal PSA kinetics. MAIN OUTCOMES AND MEASURES: Mechanism-based mathematical biomarkers (adaptive therapy score, expected TTP, and expected mean daily dose) were derived from first-cycle PSA kinetics. Outcomes included in silico benchmarking experiments and retrospective validation against clinical TTP and OS. Performance was benchmarked against standard phenomenological PSA metrics (eg, PSA nadir, time to nadir, and doubling time). RESULTS: Overall, data from 53 patients across 2 clinical trials were included. In the CSPC cohort of 40 patients, the adaptive therapy score derived from first-cycle data was highly prognostic for prolonged clinical TTP (univariable hazard ratio [HR], 0.49; 95% CI, 0.31-0.76; P = .002). In the mCRPC cohort of 13 patients, the adaptive therapy score exhibited a strong rank correlation with clinical TTP (Spearman ρ = 0.76; P = .002) and was associated with prolonged TTP (HR, 0.41; 95% CI, 0.16-1.07; P = .07). Analysis of long-term survival data in the mCRPC cohort demonstrated that both the adaptive therapy score and expected TTP were significantly associated with prolonged OS, whereas standard empirical PSA metrics displayed no association with OS. CONCLUSIONS AND RELEVANCE: In this modeling and validation study, mechanism-based mathematical biomarkers derived from the initial-cycle PSA dynamics accurately predicted patient-specific outcomes and survival, outperforming traditional phenomenological PSA monitoring. These accessible metrics could act as a mathematically informed decision support framework to stratify patients into personalized treatment protocols.
引用
- Gallagher K, Strobl MA, Gatenby RA, et al. Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer. JAMA Oncol. 2026. PMID: 42560686. doi:10.1001/jamaoncol.2026.2781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。